Overall rank by patents
#5,265
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Biomet Biologics, Llc
USPTO PatentsView assignee record — 65 granted patents across 27 technology areas, active 2015–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
65
Total patents granted
27
CPC technology areas
19.0
Avg claims per patent
-93%
5-year filing velocity
The verdict
Biomet holds 65 US patents across 27 technology areas — rank #5,265 of 50,000 tracked assignees.
- #5,265
- of 50,000 US assignees by volume
- Top 26%
- by Innovation Score (44.2/100)
- 19.0
- avg claims per patent
- -93%
- filing velocity, last 5 yrs
Portfolio overview
Biomet Biologics, LLC has been granted 65 US utility patents between 2015 and 2021, placing Biomet Biologics, LLC at rank #5,265 across all assignees tracked by PlainPatent. This portfolio spans 27 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.0 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Biomet Biologics, LLC is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 44.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 61 in the 2015–2019 window — a -93% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Biomet Biologics, LLC's 19.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 27 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Biomet Biologics, LLC against peers pursuing similar technology classes.
How does Biomet compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Biomet Biologics ◀ 65
Biomet Biologics, LLC
65 patents
What this shows Biomet holds 65 patents — placing it at rank #5,265 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Biomet's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
44 Top 26% higher than 74% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2021
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 18 | 27.7% |
| 2016 | 7 | 10.8% |
| 2017 | 19 | 29.2% |
| 2018 | 13 | 20.0% |
| 2019 | 4 | 6.2% |
| 2020 | 2 | 3.1% |
| 2021 | 2 | 3.1% |
Which technologies does Biomet Biologics, LLC patent most?
Top 15 of 27 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Biomet Biologics, LLC hold?
Biomet Biologics, LLC holds 65 US granted patents filed between 2015 and 2021, spanning 27 technology areas.
What is Biomet Biologics, LLC's Innovation Score?
Biomet Biologics, LLC has an Innovation Score of 44.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Biomet Biologics, LLC focus on?
Biomet Biologics, LLC's top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 37 patents. The company has filed patents in 27 CPC subclasses total.
Is Biomet Biologics, LLC's patent filing rate increasing or decreasing?
Biomet Biologics, LLC's recent filing velocity is -93% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Biomet Biologics, LLC's patents?
Biomet Biologics, LLC's patents average 19.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Biomet Biologics, LLC patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Biomet's 65 grants land it in the top 26% by Innovation Score — but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance — Biomet ranks #5,265 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61M — see who else leads that technology area. A61M leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61M technology
Biomet Biologics, LLC's primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Biomet Biologics, LLC ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov
